title: A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.
abstract: OBJECTIVE
  To describe the frequency and duration of remission in the Utrecht rheumatoid arthritis cohort of patients followed since diagnosis, and the clinical and treatment characteristics of patients with remission v those without.
  
  
  METHODS
  In 1990 the Utrecht rheumatoid arthritis cohort study group started a clinical trial in which patients with recent onset of rheumatoid arthritis (<1 year) were randomised into four treatment groups: hydroxychloroquine (n = 169); intramuscular gold (n = 163); methotrexate (n = 166); and pyramid (n = 64). After two years, rheumatologists were allowed to prescribe any disease modifying antirheumatic drug. Remission was defined as: duration of morning stiffness < or =15 min, mean VAS pain < or =10 mm, Thompson joint score < or =10, and ESR < or =30 mm/h during at least six months. Cox regression analysis was used to determine baseline clinical, demographic, and treatment predictors of remission.
  
  
  RESULTS
  Mean follow up duration was 62 months. Thirty six per cent achieved at least one period of remission. Median duration between diagnosis and the first remission period was 15 months for the intramuscular gold group, 18 months for the methotrexate and hydroxychloroquine groups, and 24 months for the pyramid group (NS). Predictors of remission were early response to initial treatment, less pain, rheumatoid factor negativity, and lower joint score at baseline.
  
  
  CONCLUSIONS
  After a mean follow up duration of 62 months, only 36% of the patients had fulfilled the remission criteria at least once. A good response to treatment during the first year seems to be independently associated with remission rather than initial treatment alone.
authors.affiliation: University Medical Centre Utrecht, Department of Rheumatology and Clinical Immunology, PO Box 85500, 3508 GA Utrecht, Netherlands. s.verstappen@azu.nl
authors.forename: S M M
authors.initials: SM
authors.lastname: Verstappen
authors.forename: G A
authors.initials: GA
authors.lastname: van Albada-Kuipers
authors.forename: J W J
authors.initials: JW
authors.lastname: Bijlsma
authors.forename: A A M
authors.initials: AA
authors.lastname: Blaauw
authors.forename: Y
authors.initials: Y
authors.lastname: Schenk
authors.forename: H C M
authors.initials: HC
authors.lastname: Haanen
authors.forename: J W G
authors.initials: JW
authors.lastname: Jacobs
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D050607:Organogold Compounds; D010147:Pain Measurement; D011379:Prognosis; D016016:Proportional Hazards Models; D012008:Recurrence; D012074:Remission Induction; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D050607:Organogold Compounds; D006886:Hydroxychloroquine; D008727:Methotrexate